Drug Trial Radar · NCT05233332
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Last checked: Nov 20, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
186
Planned (sponsor's estimate)
Start
Feb 24, 2022
Primary completion
Jan 20, 2024
Study completion Jul 20, 2024
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study consists of the two parts, phase IIa and phase IIb.
Conditions
- CRC
Interventions
HL-085Drug
12mg BID HL-085
VemurafenibDrug
720mg BID Vemurafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR(by investigator)Time frame: up to 12 months
- ORR(by ICR)Time frame: up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Oncology Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.